cfHPV DNA in Plasma of Cervical Cancer Patients
Conditions
Keywords
cfHPV DNA, cervical cancer
Brief summary
Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.
Interventions
DIAGNOSTIC_TESTAssess the risk of recurrence and the efficacy of medication
Evaluation of recurrence risk and medication efficacy through liquid biopsy
Sponsors
The Third Affiliated Hospital of Guangzhou Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy. * Patients must be older than 18 years of age. * Cervical cancer patients who are eligible for surgery and/or chemoradiotherapy. * Estimated life expectancy of more than three months. * Understands the study protocol and voluntarily participates in the research by signing the informed consent form. * Able to provide specimens and corresponding clinical information at each time point.
Exclusion criteria
* Patients who are participating in other clinical trials. * Pregnant or breastfeeding women. * Patients with severe mental illness. * Patients who voluntarily withdraw. * Patients unable to complete the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| sensitivity | 2 year | true positive rate |
Countries
China
Contacts
Primary ContactXiujie Sheng, Prof
Outcome results
None listed